Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1/2 1

Status

Completed 2

Sponsor Class

OTHER 1NETWORK 1

Study Type

Interventional 2

Sponsor

Cancer Type

Other hematologic neoplasm 2Myeloid 1

Conditions

Leukemia 2Primary Myelofibrosis 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Leukemia, Myeloid, Acute 1Leukemia, Biphenotypic, Acute 1Congenital Abnormalities 1

Interventions

Cyclophosphamide 119fludarabine phosphate 97Cytarabine 86fludarabine 74Methotrexate 70Rituximab 68Busulfan 56Whole-Body Irradiation 48Filgrastim 48Tacrolimus 43Mycophenolic Acid 43Antilymphocyte Serum 40Etoposide 37Peripheral Blood Stem Cell Transplantation 36Granulocyte Colony-Stimulating Factor 35Melphalan 34Vincristine 33Alemtuzumab 33Cyclosporine 32Clofarabine 30Azacitidine 30Dexamethasone 29Imatinib Mesylate 26thymoglobulin 25Doxorubicin 23sargramostim 22Lenalidomide 22Methylprednisolone 20Stem Cell Transplantation 19Daunorubicin 19

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Has results × Leukemia × lestaurtinib × Clear all
NCT00469859 2017-03-15

Lestaurtinib, Cytarabine, and Idarubicin in Treating Younger Patients With Relapsed or Refractory Acute Myeloid Leukemia

Children's Oncology Group

Phase 1/2 Completed
14 enrolled 9 charts
Other hematologic neoplasm

Congenital Abnormalities, Leukemia, Leukemia, Myeloid, Acute

NCT00494585 2012-06-25

CEP-701 for PH-negative Myelofibrosis

M.D. Anderson Cancer Center

Phase 2 Completed
27 enrolled 5 charts
MyeloidOther hematologic neoplasm

Leukemia, Primary Myelofibrosis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡